Short Interest in BiomX Inc. (NYSEAMERICAN:PHGE) Expands By 38.6%

BiomX Inc. (NYSEAMERICAN:PHGEGet Free Report) saw a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 118,900 shares, a growth of 38.6% from the January 15th total of 85,800 shares. Based on an average trading volume of 214,400 shares, the short-interest ratio is presently 0.6 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of BiomX in a report on Tuesday, November 14th.

View Our Latest Research Report on BiomX

BiomX Trading Up 7.1 %

BiomX stock opened at $0.24 on Tuesday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.98. The stock has a market capitalization of $11.08 million, a price-to-earnings ratio of -0.37 and a beta of 1.26. BiomX has a one year low of $0.20 and a one year high of $0.69.

BiomX (NYSEAMERICAN:PHGEGet Free Report) last released its earnings results on Tuesday, November 14th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03). As a group, sell-side analysts forecast that BiomX will post -0.48 earnings per share for the current year.

Institutional Investors Weigh In On BiomX

An institutional investor recently bought a new position in BiomX stock. 8VC GP I LLC bought a new position in BiomX Inc. (NYSEAMERICAN:PHGEFree Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,086,191 shares of the company’s stock, valued at approximately $304,000. BiomX comprises 0.3% of 8VC GP I LLC’s portfolio, making the stock its 3rd largest position. 8VC GP I LLC owned approximately 2.36% of BiomX as of its most recent filing with the SEC. Institutional investors own 36.67% of the company’s stock.

About BiomX

(Get Free Report)

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).

Featured Articles

Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.